Natera (NASDAQ:NTRA) Stock: Insider Steven Leonard Chapman Sells 3,430 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Chapman sold 3,430 shares of the firm’s stock in a transaction dated Wednesday, October 28th. The stock was sold at an average price of $426.34, for a total value of $1,462,346.20. Following the completion of the sale, the chief executive officer directly owned 91,232 shares in the company, valued at $38,895,850.88. The trade was a 3.62% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 27th, Steven Chapman sold 2,264 shares of Natera stock. The stock was sold at an average price of $406.00, for a total value of $919,184.00.
• On Thursday, October 1st, Steven Chapman sold 1,273 shares of Natera stock. The shares were sold at an average price of $413.31, for a total value of $526,143.63.
• On Tuesday, September 1st, Steven Chapman sold 1,698 shares of Natera stock. The shares were sold at an average price of $320.99, for a total value of $545,041.02.
• On Monday, August 3rd, Steven Chapman sold 3,076 shares of Natera stock. The shares were sold at an average price of $266.39, for a total value of $819,415.64.

Natera Stock Down 5.0%

Shares of NTRA stock opened at $414.30 on Friday. The stock has a fifty day moving average of $377.06 and a 200 day moving average of $266.44. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The business had revenue of $752.75 million for the quarter, compared to the consensus estimate of $661.24 million. During the same period in the previous year, the firm earned ($0.74) EPS. The company’s quarterly revenue was up 37.7% compared to the same quarter last year. Equities analysts anticipate that Natera, Inc. will post -1.14 EPS for the current year.

Hedge Funds Weigh In On Natera

Several large investors have recently made changes to their positions in NTRA. BlackRock Inc. purchased a new position in shares of Natera in the second quarter worth $2,962,770,000. K.J. Harrison & Partners Inc bought a new position in shares of Natera during the second quarter valued at $5,117,000. Abbot Financial Management Inc. purchased a new stake in shares of Natera during the second quarter valued at $1,537,000. Eagle Health Investments LP purchased a new stake in shares of Natera during the second quarter valued at $4,302,000. Finally, BlueCrest Capital Management Ltd bought a new stake in Natera in the 2nd quarter worth about $11,695,000. 99.90% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. Royal Bank Of Canada boosted their price target on shares of Natera from $350.00 to $460.00 and gave the company an “outperform” rating in a research report on Friday, September 25th. Rothschild & Co Redburn assumed coverage on shares of Natera in a research note on Tuesday, September 8th. They issued a “buy” rating and a $385.00 price target for the company. Citigroup raised their price objective on shares of Natera from $365.00 to $480.00 and gave the stock a “buy” rating in a report on Tuesday, October 6th. Guggenheim lifted their price objective on Natera from $360.00 to $475.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Finally, Zacks Research downgraded Natera from a “hold” rating to a “strong sell” rating in a report on Friday, October 16th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $394.31.

Natera News Roundup

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera’s stock momentum remains strong after reaching a new 52-week high of approximately $436, reflecting continued investor enthusiasm for its oncology testing business and Signatera growth prospects. Natera reaches a fresh 52-week high
• Positive Sentiment: Recent ESMO oncology data, including 25 company presentations and additional Signatera evidence, could support broader clinical adoption and future revenue growth. Natera presents 25 ESMO abstracts
• Neutral Sentiment: Natera is scheduled to report third-quarter 2026 results after the market closes on November 5. The report will provide a near-term catalyst focused on Signatera testing volumes, pricing, reimbursement and profitability. Natera third-quarter results announcement
• Negative Sentiment: Several insiders sold shares this week, including the CEO, CFO and other executives. The transactions totaled roughly 11,500 shares, but each sale was made under a pre-arranged Rule 10b5-1 plan to cover tax withholding on vested equity awards, making the signal less concerning than discretionary selling. Natera insider selling
• Negative Sentiment: Zacks warned that Natera may report another quarterly loss and does not currently show the usual combination of positive estimate revisions and earnings momentum associated with a likely beat. With the stock trading well above its long-term moving averages and some valuation analyses estimating substantial downside to fair value, investors may be taking profits ahead of earnings. Natera earnings outlook

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.